FDA approves agent for RA patients who do not respond to methotrexate

Article

FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series
Image Credit: jokekung - stock.adobe.com
Image Credit: gamelover - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.